Safety and Efficacy Clinical Study of SNS-595 in Patients With Platinum-Resistant Ovarian Cancer

NCT00408603 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

183

Enrollment

INDUSTRY

Sponsor class

Conditions

Epithelial Ovarian Cancer

Interventions

DRUG: Voreloxin Injection

Sponsor

Sunesis Pharmaceuticals